Table 1.
Patient and tumor characteristics (N = 110).
| Characteristics | No. of cases (n, %) | ERBB2d16 High | ERBB2d16 Low | P-value |
|---|---|---|---|---|
| n = 43 (39%) | n = 67 (61%) | |||
| Age, years | ||||
| Median (range) | 55 (30-81) | 53 (30~61) | 56 (41~81) | 0.82 |
| Sex | ||||
| Male | 58 (53%) | 26 (60%) | 32 (48%) | 0.75 |
| Female | 52 (47%) | 17 (40%) | 35 (52%) | |
| Differentiation grade | ||||
| Poor-undifferentiated | 83 (75%) | 34 (79%) | 49 (73%) | 0.093 |
| Well-moderate | 27 (25%) | 9 (21%) | 18 (27%) | |
| TNM stage | ||||
| I-III | 98 (89%) | 35 (81%) | 63 (96%) | 0.051 |
| IV | 12 (11%) | 8 (19%) | 4 (4%) | |
| Site of tumor | ||||
| Body of stomach | 100 (91%) | 39(91%) | 61 (91%) | 0.87 |
| Cardia | 10 (9%) | 4 (9%) | 6 (9%) | |
| Number of metastatic lesions | ||||
| 0 | 98 (89%) | 35 (81%) | 63 (94%) | 0.51 |
| 1 | 5.(5%) | 2 (5%) | 3 (4%) | 0.29 |
| ≥2 | 7 (6%) | 6 (14%) | 1 (2%) | 0.36 |
| Chemotherapy | ||||
| CapeOX | 48 (47%) | 19 (44%) | 29 (43%) | 0.66 |
| SOX | 39 (29%) | 15 (35%) | 24 (36%) | 0.14 |
| Others* | 23 (24%) | 9 (21%) | 14 (21%) | 0.24 |
| Line of treatment | ||||
| 1 | 33 (30%) | 12 (28%) | 21 (31%) | 0.68 |
| 2 | 14 (13%) | 5 (12%) | 9 (13%) | 0.91 |
| ≥3 | 63 (57%) | 26 (60%) | 37 (55%) | 0.27 |
| Smoking history | ||||
| Yes | 61 (55%) | 24 (56%) | 37 (55%) | 0.51 |
| No | 49 (45%) | 19 (44%) | 30 (45%) | |
| Drinking history | ||||
| Yes | 52 (47%) | 19 (44%) | 33 (49%) | 0.52 |
| No | 58 (53%) | 24 (56%) | 34 (51%) | |
| Helicobacter Pylori infection | ||||
| Yes | 90 (82%) | 35 (81%) | 55 (82%) | 0.44 |
| No | 20 (8%) | 8 (9%) | 12 (18%) |
CapeOX ,capecitabine+oxaliplatin; SOX, S1+ oxaliplatin; *Capecitabine (n = 5); FOLFOX (n = 8); Cisplatin+5-Fu (n = 6); Cisplatin+ capecitabine (n = 4).